CAR T cell immunotherapy for human cancer | Science
Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy | NEJM
CAR-T cells and combination therapies: What's next in the immunotherapy revolution? - ScienceDirect
CAR T-cell therapy
Real-world adverse events associated with CAR T-cell therapy among adults age ≥ 65 years - Journal of Geriatric Oncology
Manufacturing success rate holds back sales of Bristol Myers' CD19 CAR-T cell therapy
Taking Stock of CAR T-Cell Therapy | Cancer Today
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia | NEJM
Frontiers | Engineered T Cell Therapy for Cancer in the Clinic
Targets of CAR-T Cell Therapy - Creative BioMart
Frontiers | Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials
Dose-dependent thresholds of dexamethasone destabilize CAR T-cell treatment efficacy | PLOS Computational Biology
CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies - The Lancet Haematology
Treatment response, survival, safety, and predictive factors to chimeric antigen receptor T cell therapy in Chinese relapsed or refractory B cell acute lymphoblast leukemia patients | Cell Death & Disease
CAR T Cells: Second-Line Treatment Option for NHL? - NCI
A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
Clinical development of CAR T cell therapy in China: 2020 update | Cellular & Molecular Immunology
Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants
Explaining the hype: CAR T cells | Signals Blog
Review: A guide to manufacturing CAR T cell therapies
